A qualitative study of international key informants argues that mental health laws may be inherently discriminatory, making ...

This winter, medical experts guide you through the latest diagnostic standards, the non-deficiency causes of fatigue, and the practical steps you can take ...

Air quality in parts of India continued to remain in the very poor to severe category on Monday, with the NCR emerging as worst-affected ...

Detailed price information for Praxis Precision Medicines Inc (PRAX-Q) from The Globe and Mail including charting and trades.

The Alabama State Department of Education recently unveiled a new digital educator preparation report card revealing teacher ...

Collaborative discussions” with the FDA encouraged Praxis to submit early next year an approval filing for its epilepsy drug. Elsewhere, Rezolute shares plunged and Centessa announced a new CEO.

An announcement from Praxis Precision Medicines ( ($PRAX) ) is now available. On December 9, 2025, Praxis Precision Medicines announced the ...

Praxis Precision Medicines Inc. (NASDAQ:PRAX) is one of the best biotech stocks to buy according to Wall Street analysts. On December 8, Praxis Precision Medicines Inc.

Clear recognition of high unmet need and urgency for the SCN2A community and plausibility of the mechanism of elsunersen ...

Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.

Positive Results in the EMBOLD study of relutrigine showed a 53% placebo-adjusted reduction in seizures (p < 0.0002), 66% increase in motor ...